BioVectra Inc. Confirms Partnership With Sandoz, Inc. to Market Docetaxel in the U.S.A.

CHARLOTTETOWN, Prince Edward Island--(BUSINESS WIRE)--BioVectra Inc. announced today it has signed agreements with Sandoz Inc. of Princeton, New Jersey, for Sandoz to commercialize and market the Abbreviated New Drug Application (ANDA) for Docetaxel for injection, the generic version of Taxotere®, developed by BioVectra.

Back to news